PharmaTelevision - Immutep`s chemo-immunotherapy approach to cancer

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Immutep`s chemo-immunotherapy approach to cancer

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Frederic Triebel, Founder of Immutep

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The Clinical scientific basis approach of products

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Munich at BIO-Europe 2010. On this show I have Frederic Treibel, who is the Founder and Chief Medical Officer of a company called Immutep based in Paris, welcome to the show.

Frederic Treibel:

Right, thank you very much.

Fintan Walton:

Could you tell us about the origin of your company?

Frederic Treibel:

Immutep is a spin-off company of our cancer Institute, Institut Gustave Roussy in France and the Serono company and well we were founded in 2001, we are basically a innovative company, we are developing active immunotherapy product for advance cancer in combination with chemotherapy up to Phase IIa trial. After that we give the product to our partner to engage into randomize trials because we don't have the resource to do that and we are saying it would be a too much you know.

Fintan Walton:

Okay, right. Let's just go back to these to so that's where you are about, but the journey in which you've taken to get to where you are, could you tell us the basis the clinical scientific basis for the approach that you are taking for your products?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Frederic Treibel

Chief Medical Officer

Frederic Treibel , was Professor in Immunology and Biotechnology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while being also involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical haematologist, Dr. Frederic Treibel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics, leading to 140 publications and 16 patents.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Immutep

Immutep is a biologics company in the fast-growing field of targeted protein-based immunotherapeutics. The Company is well-advanced in the clinic and is planning a Phase IIb/III trial. It is based near Paris, France. The Company is developing two complementary types of therapeuticproteins: new classes of human protein immunostimulatory factors for the treatment of cancer (ImmuFact and ImmuCcine). therapeuticantibodies for the modulation of the immune system in cancer, autoimmune diseases and transplantation (ImmuTune). Each type of therapeutic is based on newly-discovered pathways involved in the Lymphocyte Activation Gene-3 (LAG-3) immune control mechanism, which plays a vital role in the regulation of the immune system. These pathways were discovered by the Company's scientific founder, Dr. Frederic Treibel , initially developed in collaboration between the Institut Gustave Roussy and Merck-Serono , and then confirmed by several independent teams. This has enabled Immutep to build a distinctive platform providing diversified risks and opportunities while maintaining scientific focus.